What's the difference between Mounjaro and Zepbound?

Same molecule. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for weight management. The brand your clinician prescribes usually follows your diagnosis and insurance.

FDA-approved

Tirzepatide

Dual GIP/GLP-1 receptor agonist · Subcutaneous injection · Sold as Mounjaro, Zepbound

A dual-hormone injection (Zepbound for weight loss, Mounjaro for diabetes) that has produced the largest average weight loss of any approved GLP-1-class drug so far.

Last reviewed 2026-09-01 by the TopGLP1 Editorial Team

Educational, not medical advice. This page explains GLP-1 medications in general terms. Only a licensed clinician who knows your history can decide what's right for you.

Key takeaways

Activates two receptors (GIP + GLP-1), not just one.
Zepbound = weight loss; Mounjaro = type 2 diabetes.
Highest average weight loss of approved options (~20–23% at 15 mg).
Once-weekly injection with a 5-step dose escalation.

Tirzepatide is a once-weekly injection that activates two gut-hormone receptors instead of one: GLP-1 and GIP. It's sold as Zepbound for chronic weight management and Mounjaro for type 2 diabetes.

In head-to-head weight-management trials it has produced larger average weight loss than semaglutide — roughly 20–23% at the highest dose — making it the current benchmark for efficacy among approved medications.

Like semaglutide, it's dosed by slow escalation and is also widely dispensed in compounded form through telehealth, though the legality of compounding shifts with the medication's FDA shortage status.

How tirzepatide works

Tirzepatide is a single molecule that switches on two receptors. The GLP-1 side does what semaglutide does — slows stomach emptying, reduces appetite, and improves insulin response. The GIP side is thought to add further appetite and metabolic benefits and may help the body tolerate the GLP-1 effect.

The practical takeaway is that combining the two pathways appears to produce more weight loss for many people than GLP-1 alone, though it also means dose escalation and side-effect management still matter.

How well it works

Up to ~20–23% average body-weight loss at the highest dose.

In the SURMOUNT weight-management program, adults without diabetes lost an average of about 15% (5 mg), 19% (10 mg) and 21–23% (15 mg) of body weight over 72 weeks. A direct comparison trial (SURMOUNT-5) found tirzepatide outperformed semaglutide for weight loss.

SURMOUNT-1~15%–21% mean weight loss across doses over 72 weeks

SURMOUNT-5 (vs semaglutide)Greater average weight loss than 2.4 mg semaglutide

SURPASS (diabetes)Strong A1C reduction plus weight loss in type 2 diabetes

Dosing schedule

Zepbound starts low and increases every 4 weeks as tolerated. Not everyone needs the maximum dose — many people reach their goal at 5 or 10 mg.

Weeks 1–42.5 mg once weekly

Starter dose.

Weeks 5–85 mg once weekly

First therapeutic dose.

Weeks 9–127.5 mg once weekly

Weeks 13–1610 mg once weekly

As needed12.5 mg → 15 mg once weekly

Increase only if more effect is needed and tolerated.

Escalation is paused or slowed if side effects are significant.
A single-dose vial form has been offered at lower cash prices for some strengths.

Side effects & safety

Common

• Nausea
• Diarrhea and constipation
• Vomiting
• Reduced appetite
• Injection-site reactions

Serious (uncommon)

• Pancreatitis
• Gallbladder disease
• Same thyroid C-cell tumor boxed warning as other GLP-1 drugs
• Severe GI reactions leading to dehydration

The side-effect profile is similar to semaglutide and generally improves with time and slow dose increases. Because efficacy is higher, rapid weight loss makes gallbladder symptoms worth watching for.

What it costs

Branded (cash): $1,000–$1,300/month list for Zepbound; lower-cost single-dose vials available in some cases
Compounded (telehealth): $200–$400/month typical through telehealth when available
Insurance: Diabetes coverage (Mounjaro) is more common than obesity coverage (Zepbound). Manufacturer savings cards can substantially cut branded cash cost for eligible patients.

Who it's for — and who should avoid it

Often a good fit

People who want the highest average weight loss among approved drugs
People who didn't reach their goal on semaglutide
Adults with type 2 diabetes (as Mounjaro)

Not recommended for

Anyone with medullary thyroid carcinoma or MEN 2 history
People with prior pancreatitis (discuss risk)
People who are pregnant or breastfeeding

Common questions

For average weight loss, head-to-head data favor tirzepatide. But “better” depends on tolerability, cost, and access — many people do very well on semaglutide, and side effects are similar.